Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715811 | 0.99 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL3713236 | 0.97 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL3714130 | 0.95 | — | — | |
| SCHEMBL3708164 | 0.94 | — | — | |
| SCHEMBL3710031 | 0.91 | — | — | |
| SCHEMBL3700446 | 0.90 | — | — | |
| SCHEMBL3703025 | 0.89 | — | — | |
| SCHEMBL3707322 | 0.89 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL3709444 | 0.89 | — | — | |
| SCHEMBL3705351 | 0.87 | AGTR1 (0.44) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471782-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-07-04 | — | — | EP | claimed |
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-05-17 | — | — | US | claimed |
| EP-2471782-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471782-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2011024468-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | 興和株式会社 (JP) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AGTR2, AGTR1, PPARA | AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.